Medically reviewed by Casey Gallagher, MD Finding an effective treatment for psoriatic disease (PD) often requires trial and ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Misuse of screening tools and subsequent underdiagnosis of the condition can easily occur, even amongst specialists.

Bernstein is one of 830,000 Americans living with a chronic, inflammatory disease known as psoriatic arthritis (PsA). She recently partnered with Novartis’ PsAvor Life campaign to inspire others ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may become altered, leading to a worsening of symptoms.

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

The "Psoriatic Arthritis: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, and global and ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA). POETYK PsA-1 (ClinicalTrials.gov ...

Dr. Ruderman’s clinical focus is on Rheumatoid Arthritis, Psoriatic Arthritis (combined program with Dermatology), Spondyloarthritis. Dr. Gordon has received honoraria or research support from ...

At week 16, both trials showed a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response compared with placebo. Topline data were announced from two phase 3 ...